Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Longitudinal clonotype tracking by next-generation sequencing (NGS) based T-cell receptor (TCR) rearrangement measurable residual disease (MRD) assay in frontline adult T-acute lymphoblastic leukemia (ALL)

View Full Paper
Ask AI
Bookmark
Share

Authors

NKNiranjan KhaireTKTapan KadiaJSJayastu Senapati

Discussion

Loading...

Member takes

Overview

Longitudinal clonotype tracking shows higher relapse risk in adults with T-ALL, suggesting NGS MRD is prognostic.

Key Points

  • To evaluate longitudinal patterns of TCR clonotype tracking using NGS in adult T-ALL.
  • NGS MRD assay performed on patients achieving CR on frontline therapy
  • Assessment of TCR clonotype tracking and MRD status over time
  • Evaluation of treatment regimens including hyper-CVAD and venetoclax
  • 39 adults with T-ALL included, with a median follow-up of 28.43 months.
  • 26 patients had both TCRG and TCRB sequences trackable; 10% proceeded to allo SCT.
  • Cumulative incidence of relapse was 12% in NGS negative group and 38% in NGS positive group.

Cite This Study

Khaire et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8a4https://doi.org/10.1182/blood-2025-5150
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring2025
  2. 2Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing2024 · 4 citations
  3. 3Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL2025 · 9 citations
  4. 4A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  5. 5Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia2024 · 1 citations